🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

RecruitingPhase 2Ages 18 Years - anyAllBlokhin's Russian Cancer Research Center
NCT07747740 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective, randomized, open-label, phase II clinical trial compares two sequential intravesical chemotherapy regimens in patients with bacillus Calmette-Guérin (BCG)-unresponsive high-grade non-muscle-invasive bladder cancer (NMIBC) following complete transurethral resection of bladder tumor (TURBT). Participants are randomized in a 1:1 ratio to receive sequential intravesical gemcitabine plus docetaxel or sequential intravesical gemcitabine plus mitomycin C. The primary objective is to compare 12-month event-free survival between treatment groups. Secondary objectives include evaluation of cystectomy-free survival, progression-free survival, treatment safety, tolerability, and patient-reported quality of life.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥18 years. 2. Histologically confirmed BCG-unresponsive non-muscle-invasive urothelial bladder cancer (NMIBC). 3. Complete transurethral resection of bladder tumor (TURBT) before study treatment. 4. Intermediate- or high-risk NMIBC according to current clinical guidelines. 5. Candidate for intravesical chemotherapy. 6. ECOG performance status 0-2. 7. Adequate hematologic, renal, and hepatic function. 8. Written informed consent. Exclusion Criteria: 1. Muscle-invasive (≥T2), locally advanced, or metastatic urothelial carcinoma. 2. Upper urinary tract urothelial carcinoma requiring treatment. 3. Previous hypersensitivity to gemcitabine, docetaxel, mitomycin C, or formulation components. 4. Active uncontrolled urinary tract infection. 5. Pregnancy or breastfeeding. 6. Concurrent participation in another interventional clinical trial. 7. Any serious uncontrolled medical condition that, in the investigator's opinion, would interfere with study participation or interpretation of results.
💊

What it tests

  • Gemcitabin
  • Docetaxel
  • Mitomicin C
📍

Where

1 site
N.N. Blokhin National Medical Research Center of Oncology
Moscow, Russia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy